Work

A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps9147

Authors: D. Ross Camidge, Joshua E. Reuss, Alexander I. Spira, Pasi A. Janne, Muneeb Rehman, Jonathan A. Pachter, Gloria Patrick, Louis J. Denis, David R. Spigel

Institutions: University of Colorado Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, Verastem (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281763928

Cites:

Cited by: 4

Related to: 10